by Cal Strode | Aug 16, 2023
In a wide-ranging interview with POLITICO reporter Robert King at the Next Generation of Health Care Therapies event, Dr. Peter Marks, Director, Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA), discussed cell and gene...
by Stacey Johnson | Jun 16, 2023
The definition of a rare disease in the U.S. is under 200,000 patients. The 10 per cent of Americans living with a rare disease is equivalent to 30 million people. Put another way, that is close to the entire population of Canada (at 39 million). There are 7,000 –...
by Cal Strode | Jan 5, 2023
In 2022, the UK’s Cell and Gene Therapy Catapult (aka CGT Catapult) celebrated its tenth anniversary (congratulations!) marking 10 years of accelerating innovation in cell and gene therapies (CGTs) in the UK. Much like CCRM, CGT Catapult was established as an...
by Stacey Johnson | Nov 25, 2022
If manufacturing is the gatekeeper to success in the cell and gene therapy space, it’s not surprising that the topic regularly comes up when industry leaders come together to discuss the future or to tackle the challenges we face in commercializing cell and gene...
Comments